Table 2 Significantly Mutated Genes
Study | Significantly Mutated Genes | Total |
|---|---|---|
ESCC | ||
 Jia R [30] | TP53(41.6%) NOTCH1(16.7%) CCND1(12.5%) | 24 |
 Luo H [34] | TP53(75%) NOTCH1(25%) | 11 |
 Liu T [35] | TP53(56.6%) PIK3CA(16.9%) | 55 |
 Hsieh CC [36] | NG |  |
 Wang X [38] | TP53(85.7%) PRSS3(21.4%) CDKN2A(17.9%) ART(14.3%) | 40 |
 Zhang R [39] | NG |  |
 Fujisawa R [46] | TP53(78.3%), NFE2L2 (12.1%) AJUBA(9.1%) | 42 |
 Morimoto Y [41] | TP53(85%) CDKN2A(9.1%) NFE2L2 (9.1%) | 11 |
 Yang D [43] | TP53(75%) | 10 |
EAC | ||
 Ococks E [29] | TP53(15%) APC(8%) KRAS(6%) | 97 |
 Davidson M [32] | NG | 24 |
 Openshaw MR [33] | TP53(84%) CCND1(24%) CCNE1(14%) VEGFA(14%) | 40 |
 Maron SB [12] | TP53(53%) HER2 (17%) EGFR (17%) KRAS (15%) | 183 |
 van Velzen MJM [16] | TP53(60%) KRAS(22%) | 72 |
 Eyck BM [40] | TP53(87%) CDKN2A(16.1%) KRAS (9.7%) SMAD4 (6.5%) | 31 |
 Cabalag CS [42] | TP53(80%) | 62 |
 Wallander K [44] | NG | 10 |
 van den Ende T [45] | NG |  |
 Mehta R [48] | NG |  |
 Lander EM [47] | NG |  |
EAC + ESCC | ||
 Azad TD [31] | TP53(71.1%) ERBB2(11.1%) CDKN2A(6.3%) | 45 |
 Hofste LSM [37] | TP53(60%) | 78 |